Greys Anatomy Sneak Peek 11.07 – Could We Start Again, Please? (2) – Video


Greys Anatomy Sneak Peek 11.07 - Could We Start Again, Please? (2)
Could We Start Again, Please? Secrets about Amelia #39;s past addictions come to light and cause problems for her at the hospital; Bailey oversees Jo #39;s first solo surgery; and Arizona...

By: BlueSky6134

Read the rest here:
Greys Anatomy Sneak Peek 11.07 - Could We Start Again, Please? (2) - Video

Joe Rogan Experience #574 – Dr. Mark Gordon, Matthew Gosney & Jason Hall – Video


Joe Rogan Experience #574 - Dr. Mark Gordon, Matthew Gosney Jason Hall
Dr. Mark Gordon is the Medical Director of Education at Access Medical Laboratory and is recognized as a top leader world wide in Interventional Endocrinology (Anti Aging Medicine). Matthew...

By: PowerfulJRE

Continued here:
Joe Rogan Experience #574 - Dr. Mark Gordon, Matthew Gosney & Jason Hall - Video

Merck And BIND To Develop Nanomeds For Cancer

By Estel Grace Masangkay

Clinical stage nanomedicine platform company BIND Therapeutics announced that it has signed a joint R&D agreement with Merck to develop novel nanomedicines for oncology.

According to the terms of the agreement, BIND will use its Medicinal Nanoengineering proprietary platform to build targeted Accurins that will be based on investigational KSP and PLK1 inhibitors selected from Mercks preclinical oncology portfolio. The partnership could potentially include additional Merck compounds in the future. BIND will take the lead in funding and conducting R&D activities to move Accurin candidates through first-in-human trials. Merck and BIND will then have alternate options to choose whether or not to develop and market the Accurin products. If BIND chooses to pursue further development, Merck will be eligible to receive royalty payments once the products reach the market. However, if Merck assumes responsibility for further development, it will pay BIND a fee based on R&D expenses with additional royalty payments on future sales. No further financial terms of the agreement were disclosed by either company.

Accurins are nanoparticles that are used to encapsulate anticancer drugs in a biodegradable polymer shell, which carries the drug to the targeted cancer cells and can keep healthy cells safe. The first two compounds from Merck will include a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor, which are both regulators of cell mitosis and which play a part in enabling cancer cells to multiply. KSP and PLK1 pathways are considered difficult to target using traditional agents due to therapeutic index limitations.

Scott Minick, CEO of BIND Therapeutics, said, This is an exciting and unique collaboration for BIND as it provides us with novel proprietary payloads to develop as Accurin product candidates for our internal pipeline. BIND recently saw a previous partnership with Amgen fizzle out in July, which caused its shares to drop in value in September. The new deal with Merck validates its technology and position in the nanomedicine field, the company said.

Dr. Eric Rubin, VP of clinical oncology at Merck Research Laboratories, said, We are pleased to collaborate with BIND Therapeutics to expand Merck's active oncology discovery programs. We look forward to combining compounds from our oncology portfolio with BIND's nanomedicine technology platform.

Link:
Merck And BIND To Develop Nanomeds For Cancer

Regulatory and scientific complexity of generic nanodrugs could delay savings for patients

PUBLIC RELEASE DATE:

12-Nov-2014

Contact: Michael Bernstein m_bernstein@acs.org 202-872-6042 American Chemical Society @ACSpressroom

Nanomedicine is offering patients a growing arsenal of therapeutic drugs for a variety of diseases but often at a cost of thousands of dollars a month. Generics could substantially reduce the price tag for patients -- if only there were a well-defined way to make and regulate them. An article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, details the challenges on the road to generic nanodrugs.

Matt Davenport, a C&EN contributing editor, points out that in small-molecule therapeutics -- aspirin, for example -- the active ingredient is the primary concern of regulators. For these drugs, making generic versions is a relatively straightforward process. Nanomedicine, on the other hand, is far more complicated. It often involves packaging an active ingredient inside engineered delivery systems made out of materials such as lipids, polymers or carbohydrates. Even slight changes to a nanodrug's structure can result in a different toxicity level.

To date, the Food and Drug Administration (FDA) has approved dozens of nanodrugs although it has no formal regulatory definition for what a nanodrug is. Such a definition would be a first step toward clearer regulations.

The agency currently examines each nano therapeutic on a case-by-case basis and offers guidance to drug makers that is nonbinding for now. Still, in 2013, the FDA signed off on what many consider to be the first generic therapeutic in this category, but no one is sure when the next approval might come.

###

The American Chemical Society is a nonprofit organization chartered by the U.S. Congress. With more than 161,000 members, ACS is the world's largest scientific society and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.

Link:
Regulatory and scientific complexity of generic nanodrugs could delay savings for patients

Behavioral changes seen after sleep learning

PUBLIC RELEASE DATE:

11-Nov-2014

Contact: Yivsam Azgad news@weizmann.ac.il 972-893-43856 Weizmann Institute of Science @WeizmannScience

New Weizmann Institute research may bring the idea of sleep learning one step closer to reality. The research, which appeared today in The Journal of Neuroscience, suggests that certain kinds of conditioning applied during sleep could induce us to change our behavior. The researchers exposed smokers to pairs of smells - cigarettes together with that of rotten eggs or fish - as the subjects slept, and then asked them to record how many cigarettes they smoked in the following week. The study revealed a significant reduction in smoking following conditioning during sleep.

Dr. Anat Arzi in the group of Prof. Noam Sobel of the Weizmann Institute's Neurobiology Department had previously shown that associative conditioning - Pavlovian-type learning in which the brain is trained to subconsciously associate one stimulus with another - could occur during sleep if odors were used as the unconditioned stimulus. Though the volunteers did not remember the odors they had smelled in the night, their sniffing gave them away: The next morning they reacted unconsciously to tones that had been paired with bad smells by taking short, shallow breaths. The use of smell, explains Arzi, is central: As opposed to other types of sensory stimulus, even very bad odors do not wake us.

The current study was performed on 66 volunteers who wanted to quit smoking, but were not being treated for the problem. Cigarette smoking was chosen for the study because it is behavior that can be simply quantified and the target stimulus was another smell. After filling out questionnaires about their smoking habit, those in the sleep group spent a night in the department's special sleep lab, in which their sleep patterns were closely monitored. At certain stages of sleep, they were exposed to paired smells - cigarettes and a foul odor - one right after the other, repeatedly throughout the night. Although they did not remember smelling the odors the next morning, the subjects reported smoking less over the course of the next week. In contrast, subjects who were exposed to the paired smells when awake did not smoke less afterward, nor did sleepers who were exposed to cigarette smells and the two aversive smells unpaired, at random times.

The scientists noted that the group with the best results - an average of 30% fewer cigarettes - was comprised of those who had been exposed to the smells during stage 2, non-REM sleep. This supported the group's earlier findings which suggested that we mostly forget what happens in our dreams, but conditioning that makes its way into our subconscious during the "memory-consolidation" stage may stick.

Sobel and Arzi suggest that olfactory conditioning may be a promising direction for addiction research because the brain's reward center, which is involved in such addictive behavior as smoking, is closely interconnected with the regions that process smell. Some of these regions not only remain active when we sleep, the information they absorb may even be enhanced in slumber.

Arzi: "We have not yet invented a way to quit smoking as you sleep. That will require a different kind of study, altogether. What we have shown is that conditioning can take place during sleep, and this conditioning can lead to real behavioral changes. Our sense of smell may be an entryway to our sleeping brain that may, in the future, help us to change addictive or harmful behavior."

###

More:
Behavioral changes seen after sleep learning

Combs named KSTA science teacher of the year

FLEMINGSBURG | A Fleming County teacher has been named middle school science teacher of the year by the Kentucky Science Teacher Association.

Simons Middle School Science teacher Cindy Combs said she found out she had received the award in October, but only received it earlier this month.

"I was very excited," she said. "I'm very honored to have received this award."

The award is presented to one science teacher each year who shows a commitment to students and to current science standards.

'Enthusiastic, dependable, hard-working and helpful' have been used to describe Mrs. Combs as a teacher, commanding the respect of her administrators and peers," said a spokesperson from KSTA.

According to Combs, she had been nominated in previous years, but had not received the award.

"This year, I resubmitted by application and I won," she said.

Combs said she is from Laurel County, but moved to Morehead in order to attend Morehead State University, where she received her bachelor's degree and master's degree in education and behavioral science. She is National Board certified and a Project Lead the Way instructor.

She had not originally planned to teach science to older students, Combs said.

"I started as an elementary teacher," she said. "I began working my way up and realized I enjoyed teaching middle school students. But, what hasn't changed is my love for science. It has always been my passion."

See more here:
Combs named KSTA science teacher of the year

Back Pain | Saltillo, MS – Chiropractic Neurology Center of Tupelo – Video


Back Pain | Saltillo, MS - Chiropractic Neurology Center of Tupelo
Back pain? Come to the Chiropractic Neurology Center of Tupelo. We take a different approach to the treatment and prevention of low back pain. Visit us: http://cnctupelo.com At Chiropractic...

By: Chiropractic Neurology Center of Tupelo

Follow this link:
Back Pain | Saltillo, MS - Chiropractic Neurology Center of Tupelo - Video

What Is The Definition Of Primary biliary cirrhosis PBC Medical School Terminology Dictionary – Video


What Is The Definition Of Primary biliary cirrhosis PBC Medical School Terminology Dictionary
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

Visit link:
What Is The Definition Of Primary biliary cirrhosis PBC Medical School Terminology Dictionary - Video

What Is The Definition Of prn Medical School Terminology Dictionary – Video


What Is The Definition Of prn Medical School Terminology Dictionary
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

Visit link:
What Is The Definition Of prn Medical School Terminology Dictionary - Video

What Is The Definition Of Primary liver cancer, adult Medical School Terminology Dictionary – Video


What Is The Definition Of Primary liver cancer, adult Medical School Terminology Dictionary
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

Continue reading here:
What Is The Definition Of Primary liver cancer, adult Medical School Terminology Dictionary - Video